adverse cardiovascular events risk, particularly those who have severe psoriatic disease or have not been prescribed diseasemodifying antirheumatic drugs. 10 Furthermore, the presence of severe psoriasis confers an additional 6.2% absolute excess risk of 10-year major adverse cardiovascular events, even after adjusting for age, sex, type 2 diabetes, hypertension, tobacco use, and hyperlipidemia. 11 Framingham Risk Scores (FRSs) underestimated cardiovascular risk in 73% of low-risk and 53% of high-risk patients with psoriasis, who were reclassified to higher-risk categories. 12 Despite these substantial data, patients with psoriasis are not actively educated, counseled, or screened for cardiovascular disease because data have been limited by the retrospective nature of population-based studies [5] [6] [7] [8] [9] [10] 13 and the limited power of prospective studies 14, 15 using novel imaging methods. Surrogate outcome measures quantifying cardiovascular risk are important. Coronary artery calcium (CAC) assessment has become widely accepted as a true measure of the total burden of atherosclerosis and the cornerstone for screening the risk of future cardiac events and improving cardiovascular risk stratification beyond traditional risk factors, especially in higher-risk groups. 16, 17 Three studies [18] [19] [20] found an association between moderate to severe psoriasis and increased CAC, yet cardiovascular risk stratification for patients with psoriasis remains the same as the general population despite increasing evidence to support this important excess in cardiovascular risk. Type 2 diabetes mellitus provides an important model of an established, high-risk disease associated with increased cardiovascular risk for comparison. Patients with psoriasis have atherogenic lipoprotein 21 and adipokine 22 profiles similar to those in patients with type 2 diabetes. Furthermore, CAC assessment is superior to traditional cardiovascular risk factors for predicting silent myocardial ischemia and short-term outcomes, 23 myocardial infarction and cardiac death, 24 and cardiovascular events (including stroke) 25 in asymptomatic type 2 diabetes. As a result, the American College of Cardiology/ American Heart Association guidelines now recommend computed tomography for CAC assessment to improve cardiovascular risk stratification in asymptomatic patients 40 years or older with type 2 diabetes. 26 The objective of this study was to compare CAC scores in patients with psoriasis with CAC scores in patients with type 2 diabetes based on the assumption that comparable increases in CAC scores would support the need for heightened awareness and appropriate screening for cardiovascular disease in patients with psoriasis.
Methods
Our study population was composed of unrelated individuals recruited from a specialty psoriasis clinic at the Baylor University Medical Center (BUMC), the Penn Diabetes Heart Study (PDHS), 27 for each model were reported. A logistic adjusted regression analysis was also performed to account for the high percentage of CAC scores of 0 in all groups. The CAC data were converted into categorical data (1 indicating any calcium and 0 indicating no calcium) to understand the effect of the disease (psoriasis or type 2 diabetes) on the presence of any calcium in the coronary arteries (CAC score >0), which were reported as odds ratios (ORs) with 95% CIs. All analyses were performed using STATA statistical software, version 12.0 (StataCorp), and P ≤ .05 was set as the threshold of statistical significance.
Our sample had more than 90% power to detect an OR of 2.3 to 2.5 using the group of individuals free of psoriasis as reference, with a frequency of nonzero CAC scores of 0.45 in patients with psoriasis and 0.3 in individuals without psoriasis. Considerations of nonzero CAC score frequencies were based on previous studies. 2] mg/dL in the control cohort, P < .001). The psoriasis and type 2 diabetes cohorts had a similar distribution of CAC in higher tertiles (CAC score >100 and CAC score >400, respectively) compared with the healthy control cohort. Table 2 summarizes the psoriasis cohort characteristics stratified by the presence of coronary calcium (CAC score of 0 and CAC score >0). Patients with psoriasis (n = 129) had median disease duration of 11 years. The mean age of psoriasis onset was 27.8 years, with a later onset in patients with CAC scores greater than 0 (25 vs 31 years, P = .02). A total of 120 patients (93.0%) had plaque-type psoriasis, and a significantly higher percentage of patients with plaque-type psoriasis had no evidence of CAC (74 [98.7%] vs 46 [85.2%] in the CAC score of 0 vs CAC score >1 groups, P = .003). A total of 66 patients (51.2%) had nail involvement, and 26 (20.2%) had nonpustular involvement of their palms and/or soles. A total of 96 patients (74.4%) were undergoing systemic therapy for a median of 3 years, with 96 patients (74.4%) receiving biological therapy. Psoriasis disease activity was generally well controlled (median Psoriasis Area and Severity Index score, 1.2; median body surface area, 4%), with 100 patients (77.5%) either clear (score of 0) or having minimal (score of 1) disease based on the Physician Global Assessment. Forty-four patients (34.1%) had concomitant psoriatic arthritis. No significant differences were observed in clinical severity scores or treatment status between the 2 groups.
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Results
Characteristics of Study Groups
Characteristics of the Psoriasis Cohort
Association of Psoriasis and Traditional Cardiovascular Risk Factors With CAC
We performed a stratified analysis based on prevalence of traditional cardiovascular risk factors in patients with psoriasis ( Figure) . Presence of any traditional risk factor in addition to psoriasis was associated with increased CAC compared with In unadjusted Tobit regression analysis of CAC compared with variables of interest, all 3 groups had significant correlations between CAC and age, male sex, and FRS 10-year risk, as would be expected ( Table 3 ). The CAC in the psoriasis cohort revealed stronger correlations with cardiovascular and cardiometabolic risk factors, including hypertension (Tobit regression ratio [TRR], 1.73, 95% CI, 0.96-2.51; P < .001), metabolic syndrome (TRR, 1.02; 95% CI, 0.20-1.83; P = .02), waist circumference (TRR, 4.74; 95% CI, 2.15-6.93; P < .001), systolic (TRR, 4.72, 95% CI, 1.76-7.69; P = .002) and diastolic (TRR, 3.66; 95% CI, 0.88-6.42; P = .01) blood pressures, FRS 10-year risk (TRR, 1.78; 95% CI, 1.00-2.55; P < .001), HDL-C level (TRR, −2.52; 95% CI, −3.81 to −1.22; P < .001), and blood glucose level (TRR, 4.96; 95% CI, 1.14-8.78; P = .01) when compared with the age-and sex-matched type 2 diabetes group. In the type 2 diabetes cohort, CAC scores more strongly correlated with current smoking (TRR, 1.02; 95% CI, 0.01-2.04; P = .04), regular exercise (TRR, 0.73; 95% CI, 0.01-1.45; P = .04), triglycerides level (TRR, 0.93; 95% CI, 0.18-1.67; P = .02), and very lowdensity lipoprotein cholesterol level (TRR, 0.70; 95% CI, 0.05-1.34; P = .03). Spearman correlation analysis also revealed similar associations as univariate regression analysis (eTable 1 in the Supplement).
Association of Psoriasis With CAC in Models Adjusted for Cardiometabolic Risk Factors
Hierarchical Tobit regression analysis ( Table 4 ) was performed to define the association between the presence of disease (psoriasis or type 2 diabetes) and CAC after adjusting for groups of confounding variables. In unadjusted analysis, type 2 diabetes (TRR, 1.12; 95% CI, 0.57-1.67; P < .001) had a stronger association with CAC than psoriasis (TRR, 0.73; 95% CI, 0.18-1.29; P = .01). However, in the final model, which was fully adjusted for age, sex, cardiovascular risk factors (LDL-C, HDL-C, triglycerides, and fasting blood glucose levels, systolic blood pressure, and tobacco use), cardiometabolic risk factors (BMI and metabolic syndrome), and medication use (aspirin, angiotensin-converting enzyme inhibitors, and statins), psoriasis was associated with CAC (TRR, 0.89; 95% CI, 0.35-1.44; P = .001) similar to the association in type 2 diabetes (TRR, 0.79; 95% CI, 0.02-1.55; P = .04).
Logistic multivariable regression models ( Table 5 ) were constructed using the same models as in the Tobit regression analysis, with CAC score greater than 0 as the outcome. Psoriasis was associated with the presence of any CAC after adjusting for age, sex, and cardiovascular risk factors, metabolic risk factors, and medication use (OR, 2.35; 95% CI, 1.12-4.94), which attenuated when BMI was added to the model (OR, 2.18; 95% CI, 0.75-6.35) in type 2 diabetes. Furthermore, when we added use of systemic or biological therapy to the models, the TRR and OR increased; however, these analyses were exploratory.
Discussion
We report 4 salient findings from our comparison of patients with psoriasis, patients with type 2 diabetes, and healthy con- trols: (1) cardiovascular risk factor profiles were similar in patients with psoriasis and type 2 diabetes when compared with age-and sex-matched controls; (2) the prevalence of moderate to severe coronary calcification (CAC mean total Agatston score >100 and >400) was similar between patients with psoriasis and type 2 diabetes and approximately 5 times greater than controls; (3) coronary calcium in patients with moderate to severe psoriasis demonstrated a similar association with known cardiovascular and cardiometabolic risk factors when compared with type 2 diabetes; and (4) the presence of CAC in patients with psoriasis persisted independent of BMI, which was not observed in patients with type 2 diabetes. Psoriasis and type 2 diabetes share common pathogenetic mechanisms with the important potential for inflammatory atherogenesis. Both are chronic inflammatory disorders that result from a complex interplay between genetic and environmental influences. They both demonstrate a predominantly proinflammatory milieu composed of tumor necrosis factor, interferon γ, interleukin (IL) 6, and IL-17 caused by imbalances in proinflammatory (helper T cell [T H 1] and T H 17) and anti-inflammatory (T -regulatory and T H 2) T-cell subsets and increased expression of proinflammatory signature genes, resulting in a chronic inflammatory state. 32, 33 This inflammation contributes to endothelial dysfunction and monocyte or macrophage recruitment, seminal events in atherogenesis.
34
Elevated markers of oxidative stress and platelet-derived microparticles have been reported in the serum of patients with psoriasis 35 and type 2 diabetes, 36 which can lead to increased endothelial activation. 34 Several epidemiologic studies [37] [38] [39] have described the high incidence of cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, and central obesity, in both of these groups. Obesity and the associated metabolic syndrome are especially important because adipose tissue is a major source of tumor necrosis factor, IL-1, IL-6, IL-8, and monocyte chemoattractant protein 1. Adipose tissues also secrete adipokines, including leptin and resistin, which can independently lead to insulin resistance and increased risk of atherogenesis.
An increased incidence of thrombo-occlusive disease was first noted in patients with psoriasis in the late 1970s. 40 Most of the data, which have driven the discussion linking psoriasis with cardiovascular disease, prognostic indicators, and patient management strategies, have been accrued during the past decade. 41 Multiple oral systemic and biological treatment strategies have produced decreased vascular inflammation with appropriate patient management in psoriasis and other immune-mediated inflammatory diseases. In recent years, various noninvasive imaging and functional markers have been studied to better understand the risk for atherosclerosis in psoriasis. 14, 42, 43 Multidetector computed tomography-derived CAC has long been recognized as a reliable surrogate marker of subclinical atherosclerosis and has immense prognostic value, especially in asymptomatic adults at intermediate cardiovascular risk. 44 Coronary artery calcium has high sensitivity, albeit only moderate specificity, for obstructive CAD. In addition, calcification is a measure of stabilized The beneficial role of CAC in cardiovascular risk assessment of type 2 diabetes has been well established. 25 However, CAC assessment in psoriasis has only been performed in a small number of case-control studies [18] [19] [20] 48, 49 (eTable 2 in the Supplement). Similar to our results, most of these studies report an increased CAC burden in patients with psoriasis when compared with controls. Although a previous study 50 found a lower risk for cardiovascular events in patients with psoriasis treated with anti-tumor necrosis factor therapy, no study to date has investigated the longitudinal effect of systemic therapy on CAC. In the present study, we found that adjustment for any systemic and biological therapy in multivariable model increased the regression ratio and OR by approximately 50%, thereby suggesting that these treatments may in fact have an association with lower CAC in patients with psoriasis. Ongoing studies [51] [52] [53] in psoriasis are investigating the effect of intensive skin disease treatment on cardiovascular disease (clinicaltrials.gov, NCT01553058, NCT02187172, and NCT01866592). These studies will elucidate the effect of biological treatment on subclinical vascular diseases. In a landmark study, Gelfand et al 5 found a significantly high incidence of myocardial infarction in patients with psoriasis from a UK-based registry of more than 500 000 patients. To our knowledge, our study is the first to investigate the prevalence of CAC in a large cohort of patients with psoriasis when compared with a matched type 2 diabetes cohort, a well-established coronary disease risk equivalent. We were also able to demonstrate a strong association between subclinical atherosclerosis and prevalence of cardiovascular and cardiometabolic risk factors in psoriasis. Our findings are certainly intriguing given the fact that our patients were relatively young, with most having their moderate to severe cutaneous disease under good therapeutic control. However, the relative presence of moderate to severe psoriasis revealed greater strength in CAC assessment than type 2 diabetes, independent of the effect of known cardiovascular and cardiometabolic risk factors. The attenuation of the association between type 2 diabetes and CAC when adjusted for BMI was not observed in psoriasis, suggesting that CAC may be mediated, in part, by adiposity in type 2 diabetes. We acknowledge certain limitations relating to our study design. The cross-sectional study design and lack of biological data limit our ability to establish a cause-effect relationship between psoriasis and atherosclerosis. Variations among different ethnic groups could not be established given that most of our study patients were white, which is the major demographic group affected with psoriasis in North America and Europe. Of note, almost all patients with psoriasis controlled their disease well with systemic or biological therapy for approximately 3 years before recruitment. This level of disease control likely underestimates the burden of subclinical atherosclerosis in our cohort. In addition, high-sensitivity C-reactive protein values were not obtained for our cohort of patients with psoriasis. As such, we were unable to adjust for this variable as a crude marker of inflammation in our models. Furthermore, a previous study by Staniak et al 19 found a doseresponse relationship between psoriatic skin severity and severe coronary calcium disease (CAC score >400). However, our study failed to find this relationship, likely because of the wellcontrolled nature of cutaneous disease plus the inclusion of previously treated patients in our study when compared with the cohort of patients with psoriasis.
Conclusions
Psoriasis increases CAC scores to the extent of what is observed in type 2 diabetes, independent of the effect of cardiovascular and cardiometabolic risk factors. Psoriasis and type 2 diabetes share similar cardiovascular risk profiles, which may predispose patients to developing coronary atherosclerosis at a relatively young age. These findings warrant early cardiovascular risk assessment and aggressive risk factor modification in those with moderate to severe psoriasis. In addition, CAC assessment may be considered in patients with psoriasis who have 2 or more traditional cardiovascular risk factors given the high prevalence of CAC observed in this study.
